stocks logo

DAWN

Day One Biopharmaceuticals Inc
$
7.230
+0.02(0.277%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
7.338
Open
7.270
VWAP
7.21
Vol
1.50M
Mkt Cap
732.85M
Low
7.065
Amount
10.81M
EV/EBITDA(TTM)
--
Total Shares
87.39M
EV
259.83M
EV/OCF(TTM)
--
P/S(TTM)
--
Day One Biopharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing targeted therapies for people of all ages with life-threatening diseases. The Company partners with clinical oncologists, families, and scientists to identify, acquire, and develop cancer treatments. The Company’s commercial product, OJEMDA (tovorafenib), is an oral, brain-penetrant, selective type II rapidly accelerated fibrosarcoma (RAF) kinase inhibitor of mutant BRAF V600, wild-type BRAF, and wild-type CRAF kinases. Its pipeline product candidates include DAY301 and VRK1 program. The DAY301 candidate is a PTK7 targeted ADC composed of a novel humanized anti-PTK7 immunoglobulin G1 monoclonal antibody (mAb), conjugated with a topoisomerase I inhibitor through a stable and hydrophilic modified valine-alanine (VA) cleavable linker. Its VRK1 program is a novel target involved in the regulation of cell division and DNA damage repair.
Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
34.94M
+326.52%
-0.351
+602.38%
39.63M
-57.73%
-0.327
-186.09%
--
--
-0.326
-48.29%
Estimates Revision
The market is revising Downward the revenue expectations for Day One Biopharmaceuticals, Inc. (DAWN) for FY2025, with the revenue forecasts being adjusted by -3.55% over the past three months. During the same period, the stock price has changed by -6.59%.
Revenue Estimates for FY2025
Revise Downward
down Image
-3.55%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-15.22%
In Past 3 Month
Stock Price
Go Down
down Image
-6.59%
In Past 3 Month
8 Analyst Rating
up Image
289.21% Upside
Wall Street analysts forecast DAWN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DAWN is 28.14 USD with a low forecast of 20.00 USD and a high forecast of 36.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
1 Hold
0 Sell
Strong Buy
up Image
289.21% Upside
Current: 7.230
sliders
Low
20.00
Averages
28.14
High
36.00
HC Wainwright & Co.
Andres Maldonado
Strong Buy
Reiterates
$36
2025-04-03
Reason
Goldman Sachs
Andrea Tan
Strong Buy
Maintains
$39 → $27
2025-03-25
Reason
JP Morgan
Anupam Rama
Buy
Maintains
$39 → $34
2025-03-05
Reason
JPMorgan analyst Anupam Rama lowered the firm's price target on Day One Biopharmaceuticals to $34 from $39 and keeps an Overweight rating on the shares. The firm updated models in the Smid-cap biotechnology group.
Needham
Ami Fadia
Strong Buy
Reiterates
$32
2025-02-26
Reason
HC Wainwright & Co.
Andres Maldonado
Strong Buy
Maintains
$40 → $36
2025-02-26
Reason
Wedbush
Robert Driscoll
Buy
Reiterates
$32
2025-02-26
Reason

Valuation Metrics

The current forward P/E ratio for Day One Biopharmaceuticals Inc (DAWN.O) is -5.54, compared to its 5-year average forward P/E of -8.09. For a more detailed relative valuation and DCF analysis to assess Day One Biopharmaceuticals Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-8.09
Current PE
-5.54
Overvalued PE
-4.69
Undervalued PE
-11.48

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-5.44
Current EV/EBITDA
-1.69
Overvalued EV/EBITDA
-0.98
Undervalued EV/EBITDA
-9.89

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
519.41
Current PS
4.23
Overvalued PS
2444.38
Undervalued PS
-1405.57

Financials

Annual
Quarterly
FY2025Q1
30.76M
Total Revenue
FY2025Q1
YoY :
-38.49%
-41.07M
Operating Profit
FY2025Q1
YoY :
-42.33%
-36.00M
Net Income after Tax
FY2025Q1
YoY :
-51.39%
-0.35
EPS - Diluted
FY2025Q1
YoY :
+26.31%
-62.81M
Free Cash Flow
FY2025Q1
90.62
Gross Profit Margin - %
FY2025Q1
N/A
FCF Margin - %
FY2025Q1
-117.02
Net Margin - %

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
167.2K
USD
4
3-6
Months
252.0K
USD
3
6-9
Months
701.0K
USD
6
0-12
Months
697.1K
USD
6
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
1.3M
Volume
1
6-9
Months
3.2M
Volume
2
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
2
1.2M
Volume
Months
6-9
1
1.2M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

DAWN News & Events

Events Timeline

2025-06-10 (ET)
2025-06-10
08:40:57
Day One Biopharmaceuticals appoints Michael Vasconcelles as Head of R&D
select
2025-05-06 (ET)
2025-05-06
16:18:25
Day One Biopharmaceuticals reports Q1 EPS (35c), consensus (44c)
select
2025-02-25 (ET)
2025-02-25
16:20:45
Day One Biopharmaceuticals reports Q4 EPS ($1.02), consensus (35c)
select
Sign Up For More Events

News

3.0
07-07NASDAQ.COM
DAY ONE BIOPHARMACEUTICALS Earnings Preview: Recent $DAWN Insider Trading, Hedge Fund Activity, and More
5.0
06-10Newsfilter
Day One Appoints Michael Vasconcelles, M.D., as Head of Research and Development
3.0
05-05Yahoo Finance
Day One Biopharmaceuticals Inc (DAWN) Q1 2025 Earnings Report Preview: What to Expect
Sign Up For More News

FAQ

arrow icon

What is Day One Biopharmaceuticals Inc (DAWN) stock price today?

The current price of DAWN is 7.23 USD — it has increased 0.28 % in the last trading day.

arrow icon

What is Day One Biopharmaceuticals Inc (DAWN)'s business?

arrow icon

What is the price predicton of DAWN Stock?

arrow icon

What is Day One Biopharmaceuticals Inc (DAWN)'s revenue for the last quarter?

arrow icon

What is Day One Biopharmaceuticals Inc (DAWN)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Day One Biopharmaceuticals Inc (DAWN)'s fundamentals?

arrow icon

How many employees does Day One Biopharmaceuticals Inc (DAWN). have?

arrow icon

What is Day One Biopharmaceuticals Inc (DAWN) market cap?